OncoSil Medical Shows Promising Interim OSPREY Registry Results in Pancreatic Cancer

OSPREY Registry Demonstrates Real-World Safety and Efficacy

OncoSil Medical (ASX:OSL) has unveiled interim results from its ongoing OSPREY Registry at ESGE Days 2026, underscoring the promising clinical profile of its OncoSil™ device in patients with unresectable locally advanced pancreatic cancer (LAPC). The data, drawn from 64 patients across Austria, Greece, Italy and Spain, reveal a robust safety record with no serious adverse device effects (SADEs) or Grade 3 or higher adverse events reported.

The registry’s real-world setting lends weight to these findings, with mild adverse events limited mostly to Grade 1 abdominal pain and a single Grade 2 fatigue case. This safety profile complements the company’s recent operational momentum, which includes a 60% increase in dose sales and expansion of treatment centres across Europe.

Encouraging Disease Control and Surgical Outcomes

OncoSil™ demonstrated strong efficacy signals, particularly in local disease control rates at 12 weeks post-implant: 91.4% for patients on first-line chemotherapy and 77.8% for those on second-line treatment. Notably, seven patients were successfully downstaged to surgical resection with curative intent, achieving a 71.4% rate of R0 margins, indicating complete microscopic tumour removal.

These outcomes suggest OncoSil™ could play a meaningful role in converting some unresectable cases into candidates for surgery, a critical step in improving long-term prognosis. The data build on the company’s recent clinical progress, including the completion of key trials and expanded market penetration across Germany, the UK, and other European countries as reported in its record dose sales report.

Survival Outcomes Surpass Historical Benchmarks

Median overall survival in the OSPREY cohort reached 20.6 months for patients implanted within four months of starting first-line chemotherapy, and 22.0 months for those implanted between four and twelve months after chemotherapy initiation. These figures compare favourably to historical survival rates of 12.7 to 18.8 months reported in prior studies evaluating gemcitabine plus nab-paclitaxel alone.

While the registry data remain interim and based on a limited sample, the survival advantage hints at OncoSil™’s potential to enhance standard care outcomes in a notoriously difficult-to-treat cancer. CEO Nigel Lange emphasised the significance of these findings, noting their consistency with earlier clinical data and real-world applicability across multiple European centres.